NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
NEOGEN CORP
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026
$11.63−0.18 (-1.52%)
Close on Oct 19, 2026
- Market cap
- $2.54B
- P/E (TTM)
- –
- Dividend yield
- –
NEOGEN CORP revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food Safety | $641.10M | $638.10M | $655.30M | $546.80M | $259.98M | $234.24M | $212.69M | $213.47M | $194.48M | $170.03M | 73.7% | +0.5% |
| Animal Safety | $229.30M | $256.60M | $268.90M | $275.65M | $267.18M | $234.22M | $205.48M | $200.71M | $203.45M | $188.24M | 26.3% | -10.6% |
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Food Safety | $63.40M | -$985.70M | $82.40M | $60.41M | $38.58M | $33.73M | $33.53M | $39.02M | $34.56M | $33.97M | -106.4% |
| Animal Safety | $24.50M | $7.30M | $39.30M | $43.33M | $52.55M | $48.69M | $39.05M | $33.88M | $39.53M | $34.84M | +235.6% |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenues | $768.20M | $797.40M | $821.80M | $715.08M | $424.66M | $376.30M | $335.54M | $339.44M | $331.29M | $303.15M | 88.3% | -3.7% |
| Service Revenues | $102.20M | $97.30M | $102.40M | $107.37M | $102.50M | $92.16M | $82.63M | $74.75M | $66.64M | $55.13M | 11.7% | +5.0% |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $445.30M | $448.70M | $459.00M | $398.44M | $209.34M | $183.20M | $164.71M | $165.88M | $149.69M | – | 51.2% | -0.8% |
| United States | $425.10M | $446.00M | $465.20M | $424.01M | $317.82M | $285.26M | $253.46M | $248.30M | $248.24M | – | 48.8% | -4.7% |
| Foreign Operations | – | – | – | – | – | – | – | – | $151.26M | $129.32M | – | – |
From the segment and revenue-disaggregation notes of Neogen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.